AGP Picks
View all

Lonquex market seen growing through 2030 as biosimilars and cancer cases rise

Nov. 4, 2026
Lonquex market seen growing through 2030 as biosimilars and cancer cases rise
By AI, Created 18:00 UTC, Nov 04, 2026, AGP -

The Business Research Company says the Lonquex market is poised for growth through 2030, driven by rising cancer incidence, broader use of long-acting supportive care drugs and expanding biosimilar competition. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - Lonquex is used to help cancer patients avoid severe neutropenia and infection risk during chemotherapy. - Demand for supportive care drugs is rising as cancer cases increase worldwide and more treatment moves into outpatient settings. - Biosimilar competition could make this class of treatment more affordable and more widely used.

What happened: - The Business Research Company published a Lonquex Global Market Report 2026 covering market size, trends and forecasts for 2026-2035. - The report says the Lonquex market will change significantly between 2026 and 2030. - North America held the largest Lonquex market share in 2025. - Asia-Pacific is projected to post the fastest growth during the forecast period.

The details: - Lonquex is the brand name for lipegfilgrastim, a long-acting granulocyte colony-stimulating factor. - The drug is used to boost white blood cell production. - Lonquex is prescribed to manage severe neutropenia in cancer patients receiving chemotherapy. - Chemotherapy can damage bone marrow and suppress neutrophil production. - The report links historical market growth to greater chemotherapy use, advances in hematology supportive care, early adoption of pegylated growth factors, improved cancer survival rates and a wider network of oncology treatment centers. - Future growth is expected to come from demand for long-acting supportive care drugs, biosimilar competition, a larger cancer patient population, outpatient oncology expansion and ongoing innovation in hematopoietic growth factors. - The report highlights a growing preference for long-acting G-CSF therapies. - Single-dose treatment regimens are also gaining traction because they can improve compliance and reduce healthcare burden. - Biosimilar development programs are expanding and changing the competitive landscape. - The report says there is also stronger focus on reducing infection risk in chemotherapy patients. - The report notes that the World Health Organization projected more than 35 million new cancer cases globally by 2050, up 77% from about 20 million in 2022. - Abbott Laboratories said in July 2025 that biosimilars had generated more than $64 billion in savings for European healthcare systems to date.

Between the lines: - The market opportunity is less about a single drug than about a broader shift in cancer supportive care toward longer-acting, lower-burden treatments. - Biosimilars appear to be expanding access while also intensifying price pressure across the category. - Faster growth in Asia-Pacific suggests oncology capacity and cancer treatment demand are rising in markets still building healthcare access.

What's next: - The report expects growth to continue through 2030 as cancer incidence rises and outpatient oncology services expand. - Biosimilar adoption and innovation in hematopoietic growth factors are likely to shape pricing, access and product strategy. - The company says the 2026 report includes new strategic intelligence tools such as market attractiveness scoring, TAM analysis, company scoring matrices, dashboards and hotspot infographics.

The bottom line: - Lonquex sits in a market that is being pushed forward by rising cancer burden, supportive care demand and biosimilar competition, with the strongest near-term growth expected outside North America.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

The Business Gazette Online

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

The Business Gazette Online

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.